These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 30657103)

  • 21. Remission in ankylosing spondylitis treated with anti-TNF-α drugs: a national multicentre study.
    Spadaro A; Lubrano E; Marchesoni A; D'Angelo S; Ramonda R; Addimanda O; Perrotta FM; Olivieri I; Punzi L; Salvarani C
    Rheumatology (Oxford); 2013 Oct; 52(10):1914-9. PubMed ID: 23878312
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Predictors of response to anti-TNF therapy in ankylosing spondylitis: results from the British Society for Rheumatology Biologics Register.
    Lord PA; Farragher TM; Lunt M; Watson KD; Symmons DP; Hyrich KL;
    Rheumatology (Oxford); 2010 Mar; 49(3):563-70. PubMed ID: 20032223
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of non-radiographic axial spondyloarthritis and ankylosing spondylitis patients--baseline characteristics, treatment adherence, and development of clinical variables during three years of anti-TNF therapy in clinical practice.
    Wallman JK; Kapetanovic MC; Petersson IF; Geborek P; Kristensen LE
    Arthritis Res Ther; 2015 Dec; 17():378. PubMed ID: 26703005
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Withdrawal of infliximab therapy in ankylosing spondylitis in persistent clinical remission, results from the REMINEA study.
    Moreno M; Gratacós J; Torrente-Segarra V; Sanmarti R; Morlà R; Pontes C; Llop M; Juanola X;
    Arthritis Res Ther; 2019 Apr; 21(1):88. PubMed ID: 30953541
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Responsiveness of the Ankylosing Spondylitis Disease Activity Score (ASDAS) and clinical and MRI measures of disease activity in a 1-year follow-up study of patients with axial spondyloarthritis treated with tumour necrosis factor alpha inhibitors.
    Pedersen SJ; Sørensen IJ; Hermann KG; Madsen OR; Tvede N; Hansen MS; Thamsborg G; Andersen LS; Majgaard O; Loft AG; Erlendsson J; Asmussen K; Johansen JS; Jurik AG; Møller J; Hasselquist M; Mikkelsen D; Skjødt T; Hansen A; Ostergaard M
    Ann Rheum Dis; 2010 Jun; 69(6):1065-71. PubMed ID: 19740906
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Predictors of Clinical Remission under Anti-tumor Necrosis Factor Treatment in Patients with Ankylosing Spondylitis: Pooled Analysis from Large Randomized Clinical Trials.
    Baraliakos X; Koenig AS; Jones H; Szumski A; Collier D; Bananis E
    J Rheumatol; 2015 Aug; 42(8):1418-26. PubMed ID: 26077401
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Drug survival and causes of discontinuation of the first anti-TNF in ankylosing spondylitis compared with rheumatoid arthritis: analysis from BIOBADABRASIL.
    Fafá BP; Louzada-Junior P; Titton DC; Zandonade E; Ranza R; Laurindo I; Peçanha P; Ranzolin A; Hayata AL; Duarte A; Silveira IG; Costa I; Macieira JC; Guedes-Barbosa LS; Bertolo MB; Sauma MF; Silva MB; Freire M; Scheinberg MA; Fernandes V; Bianchi W; Miranda JR; Pinheiro GR; Carvalho HM; Brenol CV; Pereira IA; de Castro GR; de Morais JC; Oliveira SK; de Abreu MM; Toledo RA; Pinheiro MM; Vieira WP; Valim V;
    Clin Rheumatol; 2015 May; 34(5):921-7. PubMed ID: 25851594
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Performance of ultrasound to monitor Achilles enthesitis in patients with ankylosing spondylitis during TNF-a antagonist therapy.
    Wang CH; Feng Y; Ren Z; Yang X; Jia JF; Rong MY; Li XY; Wu ZB
    Clin Rheumatol; 2015 Jun; 34(6):1073-8. PubMed ID: 25896532
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of tumor necrosis factor-alpha on sexual activity of male patients with ankylosing spondylitis.
    Dong X; Zheng Y; Shi TY; Liu HY
    Clin Rheumatol; 2015 May; 34(5):915-20. PubMed ID: 25064131
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The Sex Influence on Response to Tumor Necrosis Factor-α Inhibitors and Remission in Axial Spondyloarthritis.
    Lubrano E; Perrotta FM; Manara M; D'Angelo S; Addimanda O; Ramonda R; Punzi L; Olivieri I; Salvarani C; Marchesoni A
    J Rheumatol; 2018 Feb; 45(2):195-201. PubMed ID: 29419448
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Effects of infliximab and etanercept, two types of anti-tumor necrosis factor-alpha inhibitor on serum level of matrix metalloproteinase 3 expression in patients with ankylosing spondylitis].
    Yang CH; Huang F; Deng XH; Zhang JL; Zhang LY; Guo JH; Liang DF; Wang LS; Zhang YM
    Zhonghua Yi Xue Za Zhi; 2006 Sep; 86(35):2451-4. PubMed ID: 17156669
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The Clinical and MRI Effect of TNF-α Inhibitors in Spondyloarthritis Patients With Hip Involvement: A Real-World Observational Clinical Study.
    Zhang K; Zheng Y; Han Q; Liu Y; Wang W; Ding J; Wang Y; Zhang B; Jia J; Zheng M; Zheng Z; Zhu P
    Front Immunol; 2021; 12():740980. PubMed ID: 34659233
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Low sclerostin levels: a predictive marker of persistent inflammation in ankylosing spondylitis during anti-tumor necrosis factor therapy?
    Saad CG; Ribeiro AC; Moraes JC; Takayama L; Goncalves CR; Rodrigues MB; de Oliveira RM; Silva CA; Bonfa E; Pereira RM
    Arthritis Res Ther; 2012 Oct; 14(5):R216. PubMed ID: 23062122
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Real-life experience with switching TNF-α inhibitors in ankylosing spondylitis.
    Gulyas K; Bodnar N; Nagy Z; Szamosi S; Horvath A; Vancsa A; Vegh E; Szabo Z; Szucs G; Szekanecz Z; Szanto S
    Eur J Health Econ; 2014 May; 15 Suppl 1():S93-100. PubMed ID: 24832840
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of tapering tumor necrosis factor inhibitor on the achievement of inactive disease in patients with axial spondyloarthritis: a nationwide cohort study.
    Park JW; Kim HA; Shin K; Park YB; Kim TH; Song YW; Lee EY
    Arthritis Res Ther; 2019 Jul; 21(1):163. PubMed ID: 31272498
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Real life experience confirms sustained response to long-term biologics and switching in ankylosing spondylitis.
    Coates LC; Cawkwell LS; Ng NW; Bennett AN; Bryer DJ; Fraser AD; Emery P; Marzo-Ortega H
    Rheumatology (Oxford); 2008 Jun; 47(6):897-900. PubMed ID: 18403400
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evaluation of the frequency and intensity of COVID-19 in patients with ankylosing spondylitis under anti-TNF therapy.
    Türk SM; Öztürk Z; Karataş D; Erkorkmaz Ü; Gönüllü E
    Turk J Med Sci; 2022 Apr; 52(2):522-523. PubMed ID: 36161620
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Assessment of Response to Treatment, Remission, and Minimal Disease Activity in Axial Psoriatic Arthritis Treated with Tumor Necrosis Factor Inhibitors.
    Lubrano E; Parsons WJ; Perrotta FM
    J Rheumatol; 2016 May; 43(5):918-23. PubMed ID: 26980581
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Short-term response in new users of anti-TNF predicts long-term productivity and non-disability: analysis of Czech ATTRA ankylosing spondylitis biologic registry.
    Tužil J; Mlčoch T; Jirčíková J; Závada J; Nekvindová L; Svoboda M; Uher M; Křístková Z; Vencovský J; Pavelka K; Doležal T
    Expert Opin Biol Ther; 2020 Feb; 20(2):183-192. PubMed ID: 31736377
    [No Abstract]   [Full Text] [Related]  

  • 40. Spectral domain-optical coherence tomographic findings in patients with ankylosing spondylitis under anti-tumor necrosis factor-alpha therapy.
    Ilhan N; Ustun N; Tuzcu EA; Coskun M; Yagiz AE; Ilhan O; Parlakfikirer N
    Cutan Ocul Toxicol; 2015; 34(3):222-6. PubMed ID: 25363064
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.